請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24299
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 忻凌偉 | |
dc.contributor.author | Wan-Ru Chen | en |
dc.contributor.author | 陳婉茹 | zh_TW |
dc.date.accessioned | 2021-06-08T05:21:11Z | - |
dc.date.copyright | 2005-08-26 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-27 | |
dc.identifier.citation | 1. Gollnic, K.; S. Merbromin(mercurochrome)- a phtosensitizer for inglet oxygen reaction. J. Phtochem. Phtobiol. B, Biol. 1990, 5, 85-93.
2. Sriram, M.;Laiw, Y. C.; Wang, A. H. Molecular structure of antitumor drug steffimycine and modeling of its binding to DNA. J. Biomol. Struct. Dyn. 1991, 9, 251-269. 3. Morier-Teissier, E.; Boitte, N.; Helbecque, N.; Bernier, J. L.; Pommery, N.; Duvalet, J. L.; Fournier, C.; Hecquet, B.; Catteau, J. P.; Henichart, J. P. Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His. J. Med. Chem. 1993, 36, 2084-2090. 4. Gatto, B.; Zagotto, G.; Sissi, C.; Cera, C.; Uriarte, E.; Palu, G.; Capranico, G.; Palumbo, M. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. J Med Chem. 1996, 39, 3114-3122. 5. Fox, E. J. Mechanism of action of mitoxantrone. Neurology 2004, 63, S15-18. 6. Routier, S.; Cotelle, N.; Catteau, J. P.; Bernier, J. L.; Waring, M. J.; Riou, J. F.; Bailly, C. Salen-anthraquinone conjugates. Synthesis, DNA-binding and cleaving properties, effects on topoisomerases and cytotoxicity. Bioorg. Med. Chem. 1996, 4, 1185-1196. 7. Collier, D. A.; Neidle, S. Synthesis, molecular modelling, DNA binding and antitumor properties of some Substituted amidoan-thraquinones. J. Med. Chem. 1988, 31, 847-857. 8. Mary G. J.; Hiroshi K.; Shohei T.; Junko K.; Susan L. M.; Anthony M.; Margaret M. B.; Barry C. L.; Lee K. Antitumor agents—CLXVII. Synthesis and structure-activity correlations of the cytotoxic anthraquinone 1,4-bis-(2,3-epoxypropylamino)-9,10 -anthracenedione, and of related compounds. Bioorg. Med. Chem.1997, 5, 1469-1479. 9. Kruijtzer, J. A.; Lefeber, D. J.; Liskamp, M. J. Approaches to the Synthesis of Ureapeptoid Peptidomimetics. Tetrahedron Lett. 1997, 38, 5335-5338. 10. Marc, R.; Muriel, L.; Sylvie, D.; Annie, H.; Jean, M. A Facile Synthesis of Chiral N-Protected b-Amino Alcohols. Tetrahedron Lett. 1991, 32, 923-926. 11. Vasulinga T. R. A convenient large scale synthesis of N-Boc-ethylenediamine. Syntheic Communication. 1994, 24, 1767-1772. 12. Lapatsanis, L.; Milias, G.; Froussios, K.; Kolovos, M. Synthesis of N-2,2,2- (Trichloroethoxycarbonyl)-L-amino Acid and N-(9-Fluorenylm ethoxycarbonyl)- L-amino Acids Involving Succinimidoxy Anion as a Leaving Group in Amino Acid Protection. Synthesis. 1983, 671-673. 13. Robert, F. C., Lewis B. The triisopropylsilyl group as a hydroxyl-protecting function. J. Org. Chem. 1980, 45, 4797-4798. 14. Boeijen, A.; Ameijde, J. V.; Liskamp, M. J. Solid-Phase Synthesis of Oligourea Peptidomimetics Employing the Fmoc Protected Strategy. J. Org. Chem. 2001, 66, 8454-8462. 15. Caputo, R.; Cassano, E.; Longobardo, L.; Palumbo, G. Synthesis of enantiopure N- and C- protected homo-b-amino acids by direct homologation of a-amino acid. Tetrahedron. 1995, 51, 12337-12350. 16. Wenschuh, H.; Beyermann, M.; Haber, H.; Seydel, J. K.; Krause, E.; Stepwise Automated solid phase synthesis of naturally occurring peptaibols using FMOC Amino Acid Fluorides. J. Org. Chem. 1995, 60, 405-410. 17. Ho, P. T.; Ngu, K. An effective synthesis of N-(9-Fluorenylmethyloxycarbonyl) a-amino aldehydes from S-benzyl thioesters. J. Org. Chem. 1993, 58, 2313-2316. 18. Horwell, D. C.; Hughes, J.; Hunter, J. C.; Pritchard, M. C.; Richardson, R. S. Rationally designed “Dipeptoid” analogues of CCK. a-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxislytic properties. J. Med. Chem. 1991, 34, 404-414. 19. Somlai, C.; Peter, A.; Forgo, P.; Penke, B. One-Pot synthesis of N-protected b-chiral amino alcohols. Synth. Commun. 2003, 33, 1815 - 1820. 20. Kokotos, G.; Noula, C. Selective One-Pot conversion of carboxylic acids into alcohols. J. Org. Chem. 1996, 60, 6994-6996. 21. Carmelo, A. G.; Gino, B.; Ernesto, M.; Manlio, P.; Claudia, S.; Silvano, S.; Francis J. Chromophore-modified antitumor anthracenediones: synthesis, DNA Binding, and cytotoxic Activity of 1,4-Bis[ (aminoalkyl)aminolbenzo[g]-phthalazine-5,l0-diones. J . Med. Chem. 1995, 38, 526-536. 22. Lown, J. W.; Morgan, A. R.; Yen, S. F.; Wang, Y.-H.; Wilson,W. D. Characteristics of the Binding of the Anticancer Agents Mitoxantrone and Ametantrone and Related Structures to Deoxyribonucleic Acids. Biochemistry. 1985, 24, 4028-4035. 23. James, D. M.; Peter, H. Theoretical aspects of DNA-Protein interactions : Co-operative and Non Co-operative binding of large ligands to a one-demensional homogeneous lattice. J. Mol. Biol. 1974. 86. 469-489. 24. Klaus, P.; Zennia, P.; Ketan, C. R.; Paul, H.T.; John, A. H.; Lloyd, R. K.; Laurence, H. P.Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells. J. Med. Chem. 2004, 47, 1856-1859. 25. Bailly, C.; Routier, S.; Bernier, J.L.; Waring, M. J.DNA recognition by two mitoxantrone analogues: influence of the hydroxyl groups. FEBS Letters. 1996, 379, 269- 272. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24299 | - |
dc.description.abstract | 很多抗癌藥物具有很好細胞毒殺效果但卻沒有選擇性,增加抗癌藥物對DNA序列的選擇性可能可以減低毒性以及其他副作用。像 ametantrone 和 mitoxantrone 這類化合物抗癌方面已使用了很久的時間,有平面的蒽醌骨架的mitoxantrone 現在仍是臨床用藥。具有蒽醌類平面骨架的對於DNA的識別及結合是必須的而且在結合上DNA後進一步影響DNA的正常功能,例如轉譯RNA及複製DNA。而且這些嵌入DNA的分子可能可以辨識某些特定的鹼基對。為了改善對DNA親和力以及選擇性,設計以及平行合成蒽醌骨架這一系列化合物。我們保留了 mitoxantrone 具平面特性的三環骨架以及2-(aminoethyl)amino側鏈來接上各種胺基酸。接上的胺基酸側鏈可以對DNA產生離子作用力來加強對DNA的親和力。然而,胜肽骨架並不穩定容易被蛋白酶水解。近來在仿胜肽中很多應用了胺基甲醯基骨架替換醯胺基骨架。我們還原胺基酸並導入了 carbonyloxy 基團,再將 carbonyloxy 單體接到蒽醌骨架上,並且嘗試發展一個簡單的合成方式以便用來進行平行合成一系列具有胺基甲醯基側鏈的蒽醌類化合物。一些新的蒽醌類衍生物在人類癌細胞株上表現有不錯的細胞毒殺效果。 | zh_TW |
dc.description.abstract | Most antitumor agents are highly cytotoxic but not selective. Increasing the lignad selectivity to specific DNA sequences may reduce their toxicity and other adverse effects. Drugs containing 9,10-anthracenedione, such as ametantrone and mitoxantrone, have been used as anti-tumor agents for a long time. Now mitoxantrone, which contains a planar anthraquinone skeleton, is a clinically useful antitumor agent. The planar characteristics of the core structure 9,10-anthracenedione are necessary for molecular recognition and binding into the base pairs of DNA helix to affect transcription and replication processes of the cell . This intercalative interaction may serve as an anchor for intercalating drugs at specific sites of DNA base pair followed by cell-killing. With the aims to increase the DNA affinity and selectivity, a series of l,4-bis[(2-aminoethyl)amino] substituted9,l0-anthracenedione was designed and prepared by parallel synthesis. We reserve the planar characteristics of the core structure 9,10-anthracenedione,and the 2-(aminoethyl)amino of mitoxantrone. The 2-(aminoethyl)amino could be linked a variety of amino acids. The side chain amino acids will create ionic interaction with the ribose phosphates of the nucleic acids. Howevre, the peptide backbone is not stable to proteolytic degradation. Recently an increasing amount of attention has focused on the application of the carbamate moiety as a replacement for the amide bond in peptidomimetics. We reduced the amino acid to amino alcohol and introduced a carbonyloxy group. In order to introduce the carbonyloxy monomer to anthracqueinone skeleton, we are trying to develop a convenient general method for parallel synthesis. Several novel anthracqueinone derivatives showed significant cytotoxicoty against different houmor cancer cell lines. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:21:11Z (GMT). No. of bitstreams: 1 ntu-94-R92423013-1.pdf: 5594865 bytes, checksum: 4cc44190be58e7e84ad6447677631e60 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 中文摘要 1
英文摘要 2 1 背景與研究目的 3 1-1 背景 3 1-2 研究目的 6 2 結果與討論 7 2-1 化學合成部分 7 2-1-1 蒽醌類化合物中間體合成方法 7 2-2-2 醯胺基蒽醌類化合物合成方法 9 2-2-3 胺基甲醯基蒽醌類化合物合成方法 15 2-2 藥理部分 18 2-2-1 藥理實驗方法 18 2-2-2 藥理實驗結果 19 3 結論 30 4 實驗部分 31 4-1 試劑及溶劑來源 31 4-2 一般儀器與方法 32 4-3 合成步驟 33 5 參考文獻 87 附圖 91 | |
dc.language.iso | zh-TW | |
dc.title | 設計與合成具抗癌潛力之醯胺基及胺基甲醯基蒽醌類化合物 | zh_TW |
dc.title | Design and Synthesis of Amido- and Carbamoyl- anthraquinones as Potential Antitumor Agents | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳基旺,顧記華,孔繁璐 | |
dc.subject.keyword | 蒽,醌,類化合物,抗腫瘤, | zh_TW |
dc.subject.keyword | anthraquinone,Antitumor, | en |
dc.relation.page | 143 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2005-07-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 5.46 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。